SCHEMBL5496629

SCHEMBL5496629

O=C[C@@](O)(CO)[C@H](O)[C@H](O)CO

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.33
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18383123 1.00 AKR1B1 (0.33) AKR1B1LMNAL3MBTL1TDP1
SCHEMBL16915296 0.87 LMNA (0.40) AKR1B1LMNAL3MBTL1TDP1
SCHEMBL19512303 0.87 LMNA (0.40) AKR1B1LMNAL3MBTL1TDP1
SCHEMBL3645294 0.87 LMNA (0.40) AKR1B1LMNAL3MBTL1TDP1
Furan SCHEMBL28235587 0.86
SCHEMBL19690615 0.83 AKR1B1 (0.31) AKR1B1
SCHEMBL2598813 0.79
SCHEMBL4321542 0.79
SCHEMBL19690518 0.78
SCHEMBL28275875 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3946448-B1 SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEM IMMUNOPHOTONICS INC (US) 2025-12-10 EP disclosed
US-20250340912-A1 METHOD FOR PRODUCING 2,4-DIHYDROXY BUTYRATE OR L-THREONINE USING A MICROBIAL METABOLIC PATHWAY Technische Universität Dresden (DE) 2025-11-06 US disclosed
EP-4637800-A1 COMPOSITIONS COMPRISING AN ONCOLYTIC PEPTIDE AND CHITOSAN Lytix Biopharma AS (NO) 2025-10-29 EP disclosed
EP-4637799-A1 MEDICAL PRODUCTS CONTAINING AN AQUEOUS FORMULATION OF A PEPTIDE Lytix Biopharma AS (NO) 2025-10-29 EP disclosed
US-12398215-B2 Chitosan-derived compositions IMMUNOPHOTONICS, INC (US) 2025-08-26 US disclosed
US-20250134993-A1 GLYCATED CHITOSANS FOR TREATMENT OF VIRAL INFECTIONS IMMUNOPHOTONICS, INC. 2025-05-01 US disclosed
US-20250122313-A1 METHODS FOR PRODUCING GLYCATED CHITOSANS IMMUNOPHOTONICS, INC 2025-04-17 US disclosed
WO-2025052933-A1 COMPOSITION, AND COMPOSITIONS FOR VISCOSITY ENHANCEMENT DIC株式会社 2025-03-13 WO disclosed
US-12208081-B2 Tannin-containing gastrointestinal formulations and methods of use WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2025-01-28 US disclosed
WO-2024218102-A1 MODIFICATION OF AROMATIC POLYMERS PREFERE RESINS HOLDING GMBH (DE) 2024-10-24 WO disclosed
US-20220160753-A1 SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEM IMMUNOPHOTONICS INC (US) 2022-05-26 US disclosed
EP-3990556-A1 USE OF POLYPHENOL COMPOUNDS AND HYDROPHILIC POLYMERS FOR REDUCING OR PREVENTING COLLOIDS ADHESION AND/OR FOULING ON A SUBSTRATE RHODIA OPERATIONS (FR) 2022-05-04 EP disclosed
EP-3946448-A1 SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEM Immunophotonics, Inc. (US) 2022-02-09 EP disclosed
US-20150290227-A1 USE OF HAMAMELITANNIN FOR THE TREATMENT OF STAPHYLOCOCCAL INFECTIONS BALABAN NAOMI (US) 2015-10-15 US disclosed
WO-2007147098-A2 IDENTIFICATION AND USE OF NON-PEPTIDE ANALOGS OF RNAIII-INHIBITING PEPTIDE FOR THE TREATMENT OF STAPHYLOCOCCAL INFECTIONS TUFTS UNIVERSITY (US) 2007-12-21 WO disclosed
US-20070293435-A1 Identification and Use of Non-Peptide Analogs of RNAIII-Inhibiting Peptide for the Treatment of Staphylococcal Infections BALABAN, NAOMI 2007-12-20 US disclosed
US-6562514-B1 Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries PINNACLE VRB LIMITED (AU) 2003-05-13 US disclosed
US-6468688-B2 CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE PINNACLE VRB LIMITED (AU) 2002-10-22 US disclosed
US-20010028977-A1 Charging, discharging efficiency; vanadium electrolyte JD HOLDING INC. (KY) 2001-10-11 US disclosed
US-6143443-A ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE PINNACLE ARB LIMITED (AU) 2000-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12208081-B2 Tannin-containing gastrointestinal formulations and methods of use FABP2, FABP6, MLN AKR1B1 4587/4885LMNA 2812/4885L3MBTL1 4537/4885
US-20220160753-A1 SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEM CD40LG, CD14, CD69 AKR1B1 4718/4885LMNA 4616/4885L3MBTL1 4647/4885
US-12398215-B2 Chitosan-derived compositions CHIT1, CHIA, MUC1 AKR1B1 4174/4885LMNA 2537/4885L3MBTL1 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.